Related Experiment Video

Updated: Mar 25, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K

Increased statin eligibility based on ACC/AHA versus NCEP guidelines for high cholesterol management in Chile

Guadalupe Echeverría1, Catalina Dussaillant2, Luis Villarroel3

  • 1Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile.

Insights

New cardiovascular guidelines significantly increased statin eligibility in Chile. The American College of Cardiology and American Heart Association (ACC/AHA) recommendations expanded statin therapy for more women and older adults compared to older National Cholesterol Education Program (NCEP) guidelines.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • The 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines updated cardiovascular risk assessment and cholesterol management.
  • These guidelines modified previous recommendations from the National Cholesterol Education Program (NCEP) established in 2001.
  • The impact of the new ACC/AHA guidelines on statin eligibility in Latin America remained unquantified.

Purpose of the Study:

  • To estimate and compare statin therapy eligibility in the adult Chilean population using ACC/AHA and NCEP guidelines.
  • To assess the impact of updated cardiovascular guidelines on potential statin use in Chile.

Main Methods:

  • Cross-sectional analysis of a representative Chilean adult sample from the 2009-2010 National Health Survey (NHS).
  • Calculation of the proportion of individuals eligible for statin therapy under both ACC/AHA and NCEP guidelines.

Main Results:

  • ACC/AHA guidelines increased statin eligibility from 21.7% (NCEP) to 33.2% (a 53% rise).
  • The increase was more pronounced in women (29.6% vs. 15.6%) and individuals over 60 (75% vs. 46%).
  • Newly eligible individuals under ACC/AHA included more women, older adults, and those with lower LDL cholesterol.

Conclusions:

  • The new ACC/AHA guidelines substantially increased the number of Chilean adults eligible for statin therapy compared to NCEP.
  • Implementation of ACC/AHA guidelines has significant public health implications for Chile and potentially other Latin American countries.
  • Expanded eligibility includes more women and older adults without diagnosed cardiovascular disease, warranting further consideration.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
415
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398